Koyfin Home > Directory > Health Care > Arena Pharmaceuticals > EV / EBITDA (ltm)

Arena Pharmaceuticals EV / EBITDA (ltm) Chart (ARNA)

Arena Pharmaceuticals annual/quarterly EV / EBITDA (ltm) from 2017 to 2017. Enterprise multiple, also known as the EBITDA multiple, is a ratio used to determine the value of a company. It uses the consensus estimate EBITA over the last twelve months (LTM). The enterprise multiple looks at a firm in the way a potential acquirer might by considering the company's debt, which other multiples such as P/E do not include.
  • Arena Pharmaceuticals EV / EBITDA (ltm) for the quarter ending December 12, 2017 was 195.10 a 91.59% increase of 178.70 year over year
Other Valuation Metrics:
  • Arena Pharmaceuticals Market Cap for the quarter ending March 03, 2018 was $1,938m a 72.36% increase of 1,402m year over year
  • Arena Pharmaceuticals Price / Book for the quarter ending March 03, 2018 was 7.49 a -168.68% decrease of -12.63 year over year
  • Arena Pharmaceuticals Enterprise Value for the quarter ending March 03, 2018 was $1,752m a 70.30% increase of 1,232m year over year
View Chart On Koyfin

Quarterly ARNA EV / EBITDA (ltm) Data

12/2017195.10
09/201755.81
06/201728.25
03/201716.41

Annual ARNA EV / EBITDA (ltm) Data

2017195.10